



Dartmouth
GEISEL SCHOOL OF
MEDICINE

Therapy and prevention of long-term cognitive impairment following neonatal HSV infection

David A. Leib, PhD

Department of Microbiology & Immunology

Geisel School of Medicine, Dartmouth, Hanover, NH.

Advancing Science Series

Herpes Cure Advocacy/HVTN

October 7th, 2025



COI Statement

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 April 2020 (16.04.2020)



(10) International Publication Number
WO 2020/077119 A1

(51) International Patent Classification:

A61K 39/245 (2006.01) C07K 16/08 (2006.01)
A61K 39/29 (2006.01) C07K 16/30 (2006.01)
A61P 31/22 (2006.01) C12N 15/13 (2006.01)

(21) International Application Number:

PCT/US2019/055685

(22) International Filing Date:

10 October 2019 (10.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/744,325 11 October 2018 (11.10.2018) US

(71) Applicants: **TRUSTEES OF DARTMOUTH COLLEGE** [US/US]; 11 Rope Ferry Road, Hanover, New Hampshire 03755 (US). **DUKE UNIVERSITY** [US/US]; 2812 Erwin Road, Durham, North Carolina 27710 (US).

(72) Inventors: **ACKERMAN, Margaret E.**; 11 Rope Ferry Road, Hanover, New Hampshire 03755 (US). **BACKES, Iara M.**; 11 Rope Ferry Road, Hanover, New Hampshire 03755 (US). **LEIB, David A.**; 11 Rope Ferry Road, Hanover, New Hampshire 03755 (US). **PATEL, Chaya**

D.; 11 Rope Ferry Road, Hanover, New Hampshire 03755 (US). **MOODY, M. Anthony**; 2812 Erwin Road, Durham, North Carolina 27710 (US).

(74) Agent: **O'CONNOR, Kevin A.**; Neal, Gerber & Eisenberg LLP, Two North LaSalle Street, Suite 1700, Chicago, Illinois 60602 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: COMPOSITIONS AND METHODS FOR PREVENTING OR AMELIORATING NEONATAL HSV INFECTION


David A. Leib, Margaret Ackerman, Iara Backes, Chaya Patel (Dartmouth) and Tony Moody (Duke).

Patent WO2020077119A1 “Compositions and Methods for Preventing or Ameliorating nHSV Infection” filed 4/16/2020.



HSV epidemiology and disease


- HSV-1 ~80% seroprevalent in older adults, HSV-2 ~25%
- Cold sores, genital sores, blindness, encephalitis
- Especially devastating in neonates
- Trigger for neurodegeneration?
- Nucleoside analogs cannot treat latency
- No vaccine



HSV Pathogenesis

PRIMARY INFECTION IN MUCOSAE


HOST
IMMUNE
CONTROL




VIRUS
IMMUNE
MODULATION

LATENCY IN PNS/CNS

HSV Pathogenesis



HSV and vaccination



nature
Explore content ▾ About the journal ▾ Publish with us ▾

nature > news > article

Published: 04 January 2012

Failed herpes vaccine puzzles virologists

Heidi Ledford

Nature (2012) | Cite this article

4522 Accesses | 1 Citations | 68 Altmetric | Metrics

Researchers go back to basics in search for new approach to overcoming genital herpes.

The failure of a once-promising vaccine against the sexually transmitted herpes simplex virus has researchers struggling to determine the next step for the field.

Vical's Herpes Vaccine Bombs; Company To Exit HSV Research

By Josh Bloom — June 11, 2018

Once again, the news is bad for the millions of people who are suffering from herpes simplex virus type 2 (HSV-2), much the same as I reported in September 2017, when Genocea's experimental herpes vaccine GEN-001 was dropped after Phase II clinical trials. Today, less than a month after I interviewed Larry R. Smith, Ph.D., Vical's Senior Vice President of Research about the prospects

Success Failure

Related articles
More on Vical's Herpes Vaccine: An Interview with Larry Smith, Ph.D.
Is Vical's VCL-HB01 Genital Herpes Vaccine Ready For Big Time?
Herpes Vaccines: An Interview With Dr. William Hallford
Another Herpes Vaccine Bites the Dust (Sort of)
Herpes Vaccine Update: An

BioSpace Join the Only Global Professional Organization for Life Science Professionals

NEWS JOBS HOTBEDS CAREER RESOURCES NEWSLETTERS COMPANY PROFILE

Herpes Vaccine: Despite Setbacks, There is Still Hope

Published: Nov 29, 2019 | By Mark Terry

Science Current Issue First release papers Archive About ▾ Submit manuscript

HOME > SCIENCE > VOL. 330, NO. 6002 > PAINFUL FAILURE OF PROMISING GENITAL HERPES VACCINE

Painful Failure of Promising Genital Herpes Vaccine

Authors Info & Affiliations

SCIENCE • 15 Oct 2010 • Vol 330, Issue 6002 • p. 304 • DOI:10.1126/science.120.6002.304

765

A vaccine designed to ward off genital herpes has failed in a large clinical trial, abruptly ending the product's seemingly promising future. After 8 years of study in

NEWS COVID-19 NEWS BATTERDOWN VOTE POLYMER USE NEWS WORLD BUSINESS HEALTH NEW NEWS PULSE BIOETHICS

Herpes virus infects billions of people worldwide. Why isn't there a vaccine yet?

A vaccine to prevent herpes infections could also have an impact on slowing the spread of HIV, according to a WHO report.

Home / Vaccination

NOVEMBER 16, 2020

Are we getting closer to a herpes vaccine?

by Amy Norton Healthday Reporter



CBS NEWS NEWS SHOWS ▾ LIVE ▾ LOCAL ▾

Experimental herpes vaccine disappoints in study

BY RYAN JASLOW
JANUARY 5, 2012 / 2:55 PM EST / CBS NEWS

HSV vaccination – difficulties/opportunities


- Lifelong latency with asymptomatic shedding
- Highly prevalent, many vaccinees already seropositive
- Immune determinants incompletely defined
- Powerful immunomodulation by HSV
- Requires lifelong protection at mucosal (genital) surfaces
- nHSV only requires protection in a narrow time frame

Neonatal HSV (nHSV)


- *“Neonatal herpes is a devastating disease.....the doctor must explain to the mother that there is a high likelihood that her baby might die, or an equally high likelihood of permanent brain damage”.*

David Kimberlin M.D., The Lancet, March 2017.

- nHSV can be local or disseminated, ~1:3,000 live births.
- Disseminated disease can occur with or without skin lesions.
- Early symptoms frequently non-specific, similar to bacterial sepsis.
- ACV treatment requires clinical suspicion and often delayed.
- Even with ACV treatment, high risk of neurological sequelae remains.
- 2 months postpartum is window of susceptibility – protection window for vaccines/therapeutics?



HSV and other brain infections are associated with neurodegeneration




What are the neurological consequences of neonatal HSV?

- The developing neonatal nervous system is exquisitely sensitive to perturbation.
- Asymptomatic nHSV infections could cause significant neurological damage over a lifetime.
- 1:3,000 likely an underestimate given ubiquitous asymptomatic HSV shedding.
- New data suggest neonatal exposure >1%.
- Could clinically inapparent nHSV contribute to cognitive deficits/neurodegeneration?

HSV and other brain infections are associated with neurodegeneration

What are the neurological consequences of neonatal HSV?


- Virus Hunters (Greer Williams, 1959) quotes Jonas Salk:



Transmission patterns of neonatal HSV




HSV acquisition >28 weeks



85% of cases




Pre-partum reactivation



<1% of cases




Postnatal transmission



10-15% of cases

Transmission patterns of neonatal HSV



Suggests a role for maternal immunity in protecting neonate.


Maternal immunity: The Concept



- Maternal Ab is key for prevention of several perinatal and congenital infections.
- Maternal IgG crosses the placenta using FcRⁿ.
- Clinical evidence suggests maternal Ab protects newborns from nHSV, yet clinical translation is lacking.
- The short window (~2 months) needed for protection against nHSV provides optimism for intervention.


Can we harness maternal immunity to prevent nHSV?

- Can maternally-derived Ab protect offspring?
 - Vaccine-induced Ab (active)
 - AAV vector-expressed Ab (passive vectored)
- Experimental outline:




Maternal immunization protects neonatal mice

- Maternal immunization:
 - Live replication-defective (*d/5-29*, Knipe)
 - Subunit vaccine (gC,gD,gE, Friedman)
- Intranasally challenge pups with 1,000pfu wild type HSV:




d/5-29




Maternal immunization protects neonatal mice

- Maternal immunization:
 - Live replication-defective (*d*/5-29, Knipe)
 - Subunit vaccine (gC,gD,gE, Friedman)
- Intranasally challenge pups with 1,000pfu wild type HSV:




d/5-29

gC/gD/gE




AAV-vectored expression persists and protects


- AAV vectored expression of 3 HSV gD-specific mAbs:



Persistence of IgG expression





Survival following HSV challenge



- Vectored Ab expression is defined, persistent, and prevents mortality.


What are the neurological consequences of nHSV?

- “Psychovirology”.
- Infection of neonatal mice HSV (Patel et al, Sci Trans Med 2019):
 - Test for anxiety-like behavior (thigmotaxis) in OFT.
 - Elevated anxiety-like behavior following HSV infection.
 - *d*/5-29 maternal immunization prevents elevation of anxiety in pups.




What are the neurological consequences of nHSV?



- Survivors of nHSV often show lifelong neurological and cognitive deficits.
- Can we measure other cognitive outcomes in our nHSV model after asymptomatic infection?
- Developed a low-dose nHSV infection model (100pfu i.n.):
 - 90% survival
 - Pups gain weight normally.



Mouse model of asymptomatic nHSV





Establishing a low-dose nHSV infection model: Virus detection by PCR in CNS.




- Viral DNA detectable at 100pfu inoculum by PCR in CNS at 5dpi.

Establishing a low-dose nHSV infection model: 1000pfu i.n. infection



Assessing novel object recognition following nHSV infection



Memory, cognition

5 months post infection

Hippocampus, frontal cortex

Assessing novel object recognition following nHSV infection

Novel Object Recognition (NOR)




Familiarization

24 hours




Testing



Intact memory

vs.




Impaired memory

Memory, cognition

5 months post infection


Hippocampus, frontal cortex

Assessing novel object recognition following nHSV infection




Memory, cognition
5 months post infection
Hippocampus, frontal cortex

$$\text{Discrimination index} = \frac{\text{Time}_{\text{novel}} - \text{Time}_{\text{familiar}}}{\text{Time}_{\text{total}}}$$





Assessing novel object recognition following nHSV infection




Memory, cognition
5 months post infection
Hippocampus, frontal cortex

$$\text{Discrimination index} = \frac{\text{Time}_{\text{novel}} - \text{Time}_{\text{familiar}}}{\text{Time}_{\text{total}}}$$





Assessing novel location discrimination following nHSV infection





Spatial memory
5 months post infection
Hippocampus

$$\text{Discrimination index} = \frac{\text{Time}_{\text{novel}} - \text{Time}_{\text{familiar}}}{\text{Time}_{\text{total}}}$$





What are the neurological consequences of nHSV?

- Different paired associates learning (dPAL).
- Same test given to humans for early AD – hippocampal learning.
- Train mice to use touchscreens to perform memory tests.
- 2nd generation Bussey-Saksida Touch Screen Chambers -- to measure dPAL:






What are the neurological consequences of nHSV?

- Different paired associates learning (dPAL).
- Same test given to humans for early AD – hippocampal learning.
- Train mice to use touchscreens to perform memory tests.
- Bussey boxes, a semi automated method to measure dPAL:



What are the neurological consequences of nHSV?




Bussey box dPAL trials



- Low dose nHSV-infected mice made significantly more errors than controls on dPAL.
- Consistent with the idea of loss of hippocampal learning and short-term memory.





What are the neurological consequences of nHSV?

- Modified Barnes Maze, testing for prefrontal cortex attention and task switching.
- Train mice for 4 days to find single exit hole to home cage from a bright arena.
- 2 days off, then 2 days of reinforcement, reverse the exit hole to opposite side of the arena.
- Measure how efficiently mice can find the reversed exit hole, and where errors are made:




- nHSV causes loss of ability to task switch through prefrontal cortex.
- "Perseveration".

Quantifying HSV persistence in the CNS following low-dose nHSV infection




Quantifying HSV persistence in the CNS following low-dose nHSV infection



Low-dose nHSV infection leads to persistent CNS infection with viral genome and latency associated transcript (LAT) present in the trigeminal ganglia and CNS at 6 mpi.

Quantifying HSV-mediated damage in the CNS




- Evidence of increased myelin disruption in the infected brains, especially in the cortex

Quantifying HSV-mediated damage in the CNS



Thioflavin Quantification



- 6 months postinfection, thioflavin S staining of brains.
- Stains accumulated misfolded proteins.
- Shows increased Thioflavin S staining in hippocampus.

• Thios S staining may indicate neurodegenerative processes/accumulation of pathogenic proteins.

Summary and conclusions

- We have developed a model of subclinical HSV infection that results in cognitive decline.
- Infection results in cognitive deficits that are associated with disparate parts of the brain.
- Deficits include:
 - hippocampal associated learning and memory
 - prefrontal cortex attention & perseveration
 - spatial and short-term memory
 - demyelination and misfolded proteins in CNS.
- Maternal immunity/immunization can prevent behavioral sequelae.
- Replication-defective virus (dl5-29) does not induce behavioral sequelae.
- Ongoing work to elucidate presence of misfolded proteins/neurodegenerative markers.
- Examining the roles of acute inflammation and reactivation as sources of CNS damage.
- Intermittent antiviral therapy?

Leib Lab at Dartmouth

Abby Dutton

Evelyn Turnbaugh

Cal Garland

Roberto Alers Velazquez

Iara Backes*

Chaya Patel*

Sean Taylor*

Dartmouth

Kate Nautiyal (Psych & Brain Science)

Margie Ackerman

Harvard

David Knipe

Don Coen

Alex Balazs

University of Colorado

Christy Niemeyer

Funding

NIH/NIAD/NEI: PO1 098681, RO1 09083.



Acknowledgements



Mechanism: Mutant Virus Screen

